版本:
中国

BRIEF-Achillion announces initiation of patient dosing by Janssen in phase 2B study

Nov 30 Achillion Pharmaceuticals Inc

* Achillion announces initiation of patient dosing by Janssen in a global, short treatment-duration phase 2B study of JNJ-4178 in chronic HCV

* An ongoing phase 2A study is assessing JNJ-4178 in patients with or without compensated cirrhosis Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐